论文部分内容阅读
目的 :研究nm2 3H1和E Cadherin蛋白在非小细胞肺癌 (NSCLC)的表达及临床意义。方法 :采用S P免疫组化法测定NSCLC中nm2 3H1和E Cadherin蛋白的表达。结果 :有淋巴结转移的NSCLC组织中 ,nm2 3H1和E Cadherin蛋白阳性表达率分别为 2 9 4 % (5 / 17)和 11 8% (2 / 17) ,无淋巴结转移的则分别为 82 4 % (14 / 17)和 4 2 9% (9/ 17) ,差异有极显著意义 ,P <0 0 1或显著意义 ,P <0 0 5。nm2 3H1和E Cadherin表达与NSCLC的分期及肿瘤分化程度有关 ,P <0 0 5 ;基因蛋白表达在NSCLC组织中呈正相关 ,P <0 0 1。结论 :nm2 3H1和E Cadherin蛋白可作为判断NSCLC转移潜能及预后的重要指标
Objective: To study the expression of nm23H1 and E-Cadherin in non-small cell lung cancer (NSCLC) and its clinical significance. Methods: The expressions of nm23H1 and E-Cadherin in NSCLC were detected by SP immunohistochemistry. Results: The positive rates of nm23H1 and E-Cadherin protein in NSCLC tissues with lymph node metastasis were 294% (5/17) and 118% (2/17) respectively, while those without lymph node metastasis were 82.4% (14/17) and 42.9% (9/17), respectively. The difference was significant (P <0.01 or significant, P <0.05). The expression of nm23H1 and E Cadherin was correlated with the stage of NSCLC and the degree of tumor differentiation (P <0.05). The expression of gene protein was positively correlated with NSCLC (P <0.01). Conclusion: The nm2 3H1 and E-Cadherin proteins can be used as important markers in predicting metastasis potential and prognosis of NSCLC